Company intelligence
Alnylam Pharmaceuticals
Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.
About Alnylam Pharmaceuticals
SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-25), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and Great Place to Work. We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."
Verified activity
Signals from Alnylam Pharmaceuticals
15 published signals
Presence & Recognition
Alnylam Pharmaceuticals announced the launch of its new clinical trial program for the treatment of Alzheimer's disease.
Reported by Beverly Jo Layton Ph.D., M.P.H.
Presence & Recognition
Alnylam Pharmaceuticals is speaking at the Clinical Data Management Innovation & Clinical Trials in Rare Diseases 2026 Conference at the Marriott Princeton Forrestal in Princeton, NJ from September 9-10, 2026.
Reported by Jamie L Weiss, PhD
Presence & Recognition
Alnylam Pharmaceuticals shared its role in the journey of bringing RNAi therapeutic breakthroughs to patients in Germany.
Reported by Gilles Bertrand, PhD
Partnerships
Alnylam Pharmaceuticals collaborated with partners across the healthcare ecosystem to advance earlier recognition of ATTR-CM and support a more coordinated path to care for patients with transthyretin amyloidosis with cardiomyopathy.
Reported by Alnylam Pharmaceuticals
People
Alnylam Pharmaceuticals hired Erin Walsh as a Business Account Executive.
Reported by Erin Walsh
Presence & Recognition
Alnylam Pharmaceuticals presented new clinical data on RNAi-powered innovations, advancements in earlier diagnosis, and coordinated care in ATTR-CM at the ESC Congress in Munich.
Reported by Alnylam Pharmaceuticals
Presence & Recognition
Alnylam Pharmaceuticals shared new data from its cardiovascular portfolio at ESC 2026.
Reported by Pushkal Garg
Presence & Recognition
Alnylam Pharmaceuticals is co-organizing the RNA at the Bench and Bedside V conference with Nature Portfolio, Nature Biotechnology, Ionis Pharmaceuticals, Inc., and UC San Diego Center for RNA Technologies and Therapeutics.
Reported by Alnylam Pharmaceuticals
People
Alnylam Pharmaceuticals hired Chris Tereshko as Associate Director of Procurement Operations.
Reported by Chris Tereshko
Presence & Recognition
Alnylam Pharmaceuticals hosted its epi team at the ISPE Annual 2026 conference.
Reported by Emily Brouwer
Presence & Recognition
Alnylam Pharmaceuticals is hosting the AMCP Midwest Days of Education to network and learn about career paths and managed care.
Reported by Veeral Vyas, PharmD, RPh, PACS, PLCS, SBCS
Products & Services
Alnylam Pharmaceuticals implemented an assistant in front of thousands of people under a default deny posture and ran ten governance reviews in the first thirty days.
Reported by John Mariano
Partnerships
Alnylam Pharmaceuticals showcased how Massachusetts innovation can lead to success through public-private partnership support.
Reported by Karbert (Bert) Ng
Presence & Recognition
Alnylam Pharmaceuticals missed presentations at the ESC Congress.
Reported by Alnylam Pharmaceuticals
People
Alnylam Pharmaceuticals hired Christopher Nugent as Associate Director, Marketing Technology.
Reported by Christopher Nugent